Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.

PURPOSE To assess the frequency of expression and the prognostic significance of a hypoxia-regulated marker, carbonic anhydrase IX (CA IX), in a cohort of patients with invasive breast cancer. PATIENTS AND METHODS CA IX expression was evaluated by immunohistochemistry with a murine monoclonal antibody, M75, in a series of 103 women treated surgically for invasive breast cancer. The majority of patients were treated with adjuvant hormonal or chemotherapy. The frequency of CA IX expression, its association with recognized prognostic factors, and the relationship with outcome was evaluated by univariate and multivariate statistical analyses. RESULTS CA IX expression was present in 49 (48%) of 103 cases. The level of CA IX expression was found to be significantly associated with tumor necrosis (P <.001), higher grade (P =.02), and negative estrogen receptor status (P <.001). Furthermore, CA IX expression was associated with a higher relapse rate (P =.004) and a worse overall survival (P =.001). By multivariate analysis, CA IX was also shown to be an independent predictive factor for overall survival (hazard ratio, 2.61; 95% confidence interval, 1.01 to 6.75, P =.05). CONCLUSION CA IX expression was associated with worse relapse-free survival and overall survival in an unselected cohort of patients with invasive breast carcinoma. The potential role of CA IX as a marker of hypoxia within breast carcinomas was also indicated by a significant association with necrosis. Further work assessing its prognostic significance in breast cancer is warranted, particularly interactions with radiotherapy and chemotherapy resistance.

[1]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[2]  J. Pastorek,et al.  Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. , 1998, The American journal of pathology.

[3]  R. Kettmann,et al.  Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. , 1994, Oncogene.

[4]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[5]  W. Oyen,et al.  Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Koscielny,et al.  Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. , 1984, British Journal of Cancer.

[7]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[8]  N. Weidner,et al.  Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Wei,et al.  Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  L. Gerweck,et al.  Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. , 1996, Cancer research.

[11]  Shinichi Tanaka,et al.  Clinicopathologic Study of Angiogenesis in Japanese Patients with Breast Cancer , 1997, World Journal of Surgery.

[12]  A. Harris,et al.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer , 1992, The Lancet.

[13]  M. Stifelman,et al.  Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. , 1997, Cancer research.

[14]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[15]  S. Saga,et al.  MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas , 1999, British Journal of Cancer.

[16]  W. Sly,et al.  Immunohistochemistry of Carbonic Anhydrase Isozyme IX (MN/CA IX) in Human Gut Reveals Polarized Expression in the Epithelial Cells with the Highest Proliferative Capacity , 1998, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  R. Henriksson,et al.  Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Hewett‐Emmett,et al.  Functional diversity, conservation, and convergence in the evolution of the alpha-, beta-, and gamma-carbonic anhydrase gene families. , 1996, Molecular phylogenetics and evolution.

[19]  G. Fleuren,et al.  Therapeutic effects of monoclonal antibody g250, interferons and tumor necrosis factor, in mice with renal‐cell carcinoma xenografts , 1994, International journal of cancer.

[20]  E. Stanbridge,et al.  Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. , 1997, Cancer research.

[21]  W. Negendank,et al.  Studies of human tumors by MRS: A review , 1992, NMR in biomedicine.

[22]  J. Pastorek,et al.  Expression of MaTu‐MN protein in human tumor cultures and in clinical specimens , 1993, International journal of cancer.

[23]  M. Rubin,et al.  The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase–polymerase chain reaction assay for MN/CA9 , 1999, Cancer.

[24]  R. Gelber,et al.  Prognostic significance of tumor grade in clinical trials of adjuvant therapy for breast cancer with axillary lymph node metastasis , 1986, Cancer.

[25]  J. Griffiths.  Are cancer cells acidic? , 1991, British Journal of Cancer.

[26]  C. Redmond,et al.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update , 1983, Cancer.

[27]  A. Harris,et al.  Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast , 1999, British Journal of Cancer.

[28]  R. Gillies,et al.  ©1999 Cancer Research Campaign Article no. bjoc.1998.0455 Enhancement of chemotherapy by manipulation of tumour pH , 2022 .

[29]  A. Fyles,et al.  Oxygenation predicts radiation response and survival in patients with cervix cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  R. Tashian,et al.  The carbonic anhydrases: Widening perspectives on their evolution, expression and function , 1989, BioEssays : news and reviews in molecular, cellular and developmental biology.

[31]  G M Clark,et al.  Steroid receptors and other prognostic factors in primary breast cancer. , 1988, Seminars in oncology.

[32]  O. Vinante,et al.  Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. , 1997, Journal of the National Cancer Institute.

[33]  R. Odze,et al.  MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. , 1997, Human pathology.

[34]  T. Maren,et al.  Carbonic anhydrase: chemistry, physiology, and inhibition. , 1967, Physiological reviews.

[35]  A. Burny,et al.  Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. , 1999, The European respiratory journal.

[36]  J. Haveman,et al.  The relevance of tumour pH to the treatment of malignant disease. , 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  P. Disaia,et al.  A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. , 1996, Gynecologic oncology.

[38]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[39]  R. Kettmann,et al.  Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. , 1996, Genomics.

[40]  W. Sly,et al.  Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. , 2001, The American journal of pathology.

[41]  C. Redmond,et al.  Pathologic findings from the national surgical adjuvant breast project protocol B‐06 10‐year pathologic and clinical prognostic discriminants , 1993, Cancer.

[42]  J. Pastorek,et al.  Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. , 1997, Gastroenterology.